News & Articles

The cPass™ – SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit aims to detect the presence of neutralizing antibodies in an hour

The company aims to ramp up its production capacity of more than 50 million antibody tests per month

Test will be available at NHS laboratories across the UK, using its ARCHITECT i1000SR and i2000SR and Alinity i laboratory instruments

Interim clinical study data shows ID NOW test performance of 94.7% sensitivity and 98.6% specificity

Driven by the gap in COVID-19 testing, the collaboration aims to create a fully disposable, rapid and handheld test for consumers

A qualitative test for the detection of nucleic acid from SARS-CoV-2

Study suggests that type I IFN deficiency in the blood could help define a high-risk population

The COVID-19 vaccine trial is part of a global development program that will uncover the safety and immunogenicity of four mRNA vaccine candidates.

Test deployed on Quanterix' Simoa platform promises 1,000-fold sensitivity improvement

Assay will help guide treatment decisions in cases of non-small cell lung cancer

The company says it continues to optimize its coronavirus test amid questions about its accuracy

Collaboration with WuXi Diagnostics and Mayo Clinic on serology test will complement Thermo Fisher's widely adopted TaqPath COVID-19 molecular diagnostic test

The cutting-edge technology is utilized to aid drug development and medical equipment production

The Alinity m molecular laboratory COVID-19 test instrument claims it can run up to 1,080 tests in 24 hours

A research team at the University of Cambridge has designed a ventilator for treating COVID-19 patients that can be quickly and cheaply manufactured

Register today to reserve a place at the Summit - it opens at 13:00 (BST) / 14:00 (CEST) / 08:00 (EDT) / 05:00 (PDT) on Monday, May 11

AMSBIO's new service utilizes their novel lentiviral system to aid the development of therapeutic drugs and vaccines

Innovosens building partnerships to accelerate development, testing and market launch

The blood-based immunoassay test enables clinicians to identify the virus linked with COVID-19

The serology test promises 100% sensitivity and can help assess patients' immune response to the virus

The molecular test kit promises 100% diagnostic sensitivity and specificity, and is authorized for clinical practice use in Europe

The antibody test, which has a potential time to result of 14 minutes, will join the rest of the company's diagnostic portfolio

The company aims to provide solutions for the pandemic through close collaboration with scientists and providing cutting-edge laboratory equipment

Learn more about how BINDER is helping countless laboratories across the world conduct research into coronavirus.

Collaboration will enable global development, manufacturing and distribution of the vaccine